The European Society for Medical Oncology meeting may not be as enormous as its U.S. counterpart, but plenty of news is flowing. And some of the new data presented in Madrid over the weekend is pretty dramatic.
It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis and Roche. Now the agency is taking action, slapping new warnings to the product's label confirming that it's associated with cardiovascular risks.
Jockeying with a slew of next-generation treatments, Novartis' new anti-inflammatory drug succeeded in two Phase III trials on patients with psoriatic arthritis, stoking the company's hopes of snagging significant market share once it wins approval.
Eight months after partnering with Novartis, Emeryville, CA-based Eureka Therapeutics has landed a $21 million round led by a Chinese private equity firm. Beijing-based Yuan Capital led the round, with Majuven and all the current major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, joining in.
Novartis has notified the state of New York of its 83-employee layoff beginning Dec. 31 at its plant in Suffern, NY, a facility that will close in 2016, at which point essentially all traces of it will be eliminated.
So much for home field advantage. Switzerland plans to put the squeeze on drug prices, despite its corporate citizens Roche and Novartis. And the Basel-based companies are none too happy about the idea.
The study aims to recruit 40 people in the United Kingdom to wear watch-sized sensors on their belts. By placing the sensors around the body's center of mass the team from Imperial College London hope to gather data on each individual's position and walking speed.
Novartis is contributing $20 million to build a new, 30,000-square-foot research center at Penn that will concentrate on developing a wave of new immuno-oncology drugs.
Ophthotech says it won a $50 million enrollment milestone from Novartis for reaching a goal on its Phase III Fovista study for wet, age-related macular degeneration.
After initially leaving Novartis' meningitis B jab, Bexsero, off its national immunization program, the British government is now negotiating with the Swiss pharma over price--a series of events that's led a top Novartis Vaccines employee to tab the U.K. vaccination assessment system "flawed."